ETF of the Week: Virtus LifeSci Biotech Clinical Trials ETF (BBC)
ETF Trends publisher Tom Lydon discussed the Virtus LifeSci Biotech Clinical Trials ETF (BBC) on this week’s “ETF of the Week” podcast with Chuck…
BBC
March Madness for ETFs: 10 Funds Leading the Pack
Around the country, work places are growing increasingly restless knowing that March Madness begins Thursday and the betting pools are about to…
Biotech ETFs Jump on Gilead, Kite Deal
The biotechnology segment rallied Monday with small-cap biotech names and related exchange traded funds leading the charge after Gilead Sciences (NasdaqGS: GILD)…
ETF Performance Report: February 2017
U.S. equities and stock exchange traded funds ended February on a sullen note, with the Dow Jones Industrial Average snapping a 12-day…
Healthcare ETFs Are Latest Victim to Trump
Healthcare stocks, especially the biotech segment, and related exchange traded funds plunged Wednesday after President-elect Donald Trump singled out the rising drug…
Biotech ETFs Rally as Pence Promises ‘Orderly Transition’ Away from Obamacare
Biotechnology stocks and sector-related exchange traded funds surged Wednesday as Vice President-elect Mike Pence stated that President-elect Donald Trump’s “first order of…
Rising Rates May Hurt Small-Cap Biotech ETF Valuations
The Federal Reserve has hiked interest rates for the second time in a decade and plans to raise rates three more times…
Biotech ETFs Will Enjoy a More Favorable Environment
Now that the political overhang on the markets has more or less abated, biotechnology stocks and sector-related exchange traded funds could enjoy…
Will Trump Make Biotech ETFs Great Again?
Biotechnology exchange traded funds have rebounded after the presidential election and could find further strength under a Donald Trump administration. On the…
ETF Performance Report: October
The equities market and stock exchange traded funds ended October flat in muted action as a renewed FBI investigation into Democratic runner…
ETF Performance Report: September & Q3
U.S. equities and stock exchange traded funds strengthened in the third quarter but stuck to sideways trading through most of the past…
Biotechnology ETFs Rally on Sarepta FDA Drug Approval
Sarepta Therapeutics (NasdaqGS: SRPT) surged Monday and lifted biotechnology-related exchange traded funds after the Food and Drug Administration approved the Duchenne muscular…
Pfizer Acquires Medivation, Renews Biotech M&A Bets
Pfizer (NYSE: PFE) announced a $14 billion deal to acquire cancer drug developer Medivation (NasdaqGS: MDVN), propelling the broader biotechnology exchange traded…
BBP: An Outperforming Biotechnology ETF
The BioShares Biotechnology Products Fund (NasdaqGM: BBP) has capitalized on a string of acquisitions and outperformed other biotechnology- and pharmaceuticals-related exchange traded…